Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 3/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10003199 | 1.00 | HRH3 (0.39) | HRH3ALOX5LMNAGAAPTGDR2 | |
| SCHEMBL10003201 | 1.00 | HRH3 (0.39) | HRH3ALOX5LMNAGAAPTGDR2 | |
| SCHEMBL18332221 | 0.97 | HRH3 (0.39) | HRH3ALOX5LMNAGAAPTGDR2 | |
| SCHEMBL10002784 | 0.92 | ALOX5 (0.39) | ALOX5PTGDR2NOD2NOD1HTR6 | |
| SCHEMBL10002783 | 0.92 | ALOX5 (0.39) | ALOX5PTGDR2NOD2NOD1HTR6 | |
| SCHEMBL16188501 | 0.92 | ALOX5 (0.39) | ALOX5PTGDR2NOD2NOD1HTR6 | |
| SCHEMBL18332121 | 0.91 | HRH3 (0.40) | HRH3ALOX5LMNAGAAPTGDR2 | |
| SCHEMBL11929892 | 0.91 | HRH3 (0.38) | HRH3ALOX5LMNAGAAPTGDR2 | |
| SCHEMBL10004907 | 0.91 | HRH3 (0.38) | HRH3ALOX5LMNAGAAPTGDR2 | |
| SCHEMBL10004905 | 0.91 | HRH3 (0.38) | HRH3ALOX5LMNAGAAPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3312172-B1 | AMINOPYRAZOLE DERIVATIVES USEFUL AS SRC KINASE INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-05-06 | — | — | EP | disclosed |
| EP-3312172-A1 | AMINOPYRAZOLE DERIVATIVES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016204261-A1 | AMINOPYRAZOLE DERIVATIVES | 中外製薬株式会社 | 2016-12-22 | — | — | WO | disclosed |
| US-8829199-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20120208811-A1 | Aminopyrazole Derivative | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208811-A1 | Aminopyrazole Derivative | FGFR1, FGFR3, FGFR4 | HRH3 76/4885ALOX5 2600/4885LMNA 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.